Austin A. Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Austin A. Morris has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Jianfeng Lv
State Key Laboratory of Nuclear Physics and Technology and Institute of Heavy Ion Physics, School of Physics, Peking University, No.5 Yiheyuan Road, Haidian District, Beijing, China, Beijing, Beijing, 100871, CHINA
1 shared publication - Yuanrong Lu
Peking Univ, State Key Lab Nucl Phys & Technol, 201 Chengfu Rd, Beijing 100871, Peoples R China
1 shared publication
Latest Publications
- Open Access
- 22 January 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (4)
Advancing lithium neutron capture therapy: 6Li-loaded nanoparticles and laser-driven neutron sources
We report on 6Li neutron capture therapy (LiNCT) in anticipation of using carbon nanoparticles to deliver targeted, high linear energy transfer radiation to non-resectable tumors. Our investigations show that, compared with existing 10B neutron capture therapy (BNCT), 6Li offers similar dose potential for equal mass density (DLi∼DB when mLi=mB), for capture products that span 7 times more range and approximately three cell lengths. Consequently, 6Li-filled nanoparticles dispersed more than half-a-cell-length apart, better convey high doses and ultra-high dose-rates, as LiNCT generates substantially less γ-rays and becomes more targeted than BNCT. To this end, we propose a neutron production scheme involving laser-plasma driven protons incident on various 7Li targets, capable of producing >109 n/sr/pulse. For high repetition frequency, efficient neutron moderation, and ideal 6Li concentration, the modality offers greater precision than existing neutron capture therapy.
- 22 January 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (4)
Open AccessAdvancing lithium neutron capture therapy: 6Li-loaded nanoparticles and laser-driven neutron sources
We report on 6Li neutron capture therapy (LiNCT) in anticipation of using carbon nanoparticles to deliver targeted, high linear energy transfer radiation to non-resectable tumors. Our investigations show that, compared with existing 10B neutron capture therapy (BNCT), 6Li offers similar dose potential for equal mass density (DLi∼DB when mLi=mB), for capture products that span 7 times more range and approximately three cell lengths. Consequently, 6Li-filled nanoparticles dispersed more than half-a-cell-length apart, better convey high doses and ultra-high dose-rates, as LiNCT generates substantially less γ-rays and becomes more targeted than BNCT. To this end, we propose a neutron production scheme involving laser-plasma driven protons incident on various 7Li targets, capable of producing >109 n/sr/pulse. For high repetition frequency, efficient neutron moderation, and ideal 6Li concentration, the modality offers greater precision than existing neutron capture therapy.